PALO ALTO, Calif., Nov. 17, 2023 (GLOBE NEWSWIRE) — Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, today announced that the U.S. Patent and Trademark Office has issued…Read More
Scilex Holding Company Announces Issuance of a Second New Patent in the US for Its Lead Commercial Product ZTlido lidocaine topical system for a Method of Relieving Pain Through the Application of a NonAqueous LidocaineContaining Patch
